

Jan N Basile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3497938/publications.pdf>

Version: 2024-02-01

68
papers

4,375
citations

394421

19
h-index

155660

55
g-index

68
all docs

68
docs citations

68
times ranked

5054
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	2.2	14
2	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the <scp>REWIND</scp> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 704-712.	4.4	4
3	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. <i>Diabetes Care</i> , 2022, , .	8.6	4
4	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3448-e3454.	3.6	2
5	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq1 1 0.784314 rgBT /Overlock	13.7	197
6	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 484-490.	11.4	17
7	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 106-114.	11.4	77
8	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020, 19, 199.	6.8	14
9	Case of Episodic and Positional Hypertension. <i>Hypertension</i> , 2020, 76, 614-621.	2.7	1
10	Uncontrolled Hypertension in an Elderly Man on Multiple Antihypertensive Drugs. <i>Hypertension</i> , 2020, 76, 1658-1663.	2.7	1
11	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2922-2933.	2.9	47
12	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , The, 2020, 19, 582-590.	10.2	123
13	Hypertension in the elderly: recent developments and insights. <i>Current Opinion in Cardiology</i> , 2020, 35, 351-356.	1.8	2
14	Outcomes in adults with systolic blood pressure between 130 and 139â€šmmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial. <i>Journal of Hypertension</i> , 2020, 38, 1567-1577.	0.5	3
15	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2019, 394, 121-130.	13.7	1,625
16	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet</i> , The, 2019, 394, 131-138.	13.7	394
17	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
18	Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 629-637.	4.4	5

#	ARTICLE	IF	CITATIONS
19	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	2.7	64
20	Risk of Hospitalization for Cardiovascular Events with β -Blockers in Hypertensive Patients: A Retrospective Cohort Study. Cardiology and Therapy, 2018, 7, 173-183.	2.6	7
21	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	13.7	526
22	Design and baseline characteristics of participants in the <sc>Researching cardiovascular </sc>events with a <sc>Weekly </sc>IN</sc>cretin in <sc>Diabetes </sc>(REWIND</sc>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	4.4	160
23	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	6.1	364
24	From the President, American Society of Hypertension. Journal of the American Society of Hypertension, 2017, 11, 697.	2.3	1
25	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An <sc>ACCOMPLISH</sc> Substudy. Journal of Clinical Hypertension, 2016, 18, 299-307.	2.0	26
26	Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial. Hypertension, 2016, 68, 888-895.	2.7	103
27	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. Hospital Practice (1995), 2016, 44, 9-20.	1.0	1
28	Ambulatory blood pressure monitoring to diagnose hypertensionâ€”an idea whose time has come. Journal of the American Society of Hypertension, 2016, 10, 89-91.	2.3	3
29	Analysis of Recent Papers in Hypertension Treatment of Hypertension in the Setting of Acute Intracerebral Hemorrhage: Still No Clear Answer on the Best <sc>BP</sc> Level to Intervene or What <sc>BP</sc> Goal to Achieve. Journal of Clinical Hypertension, 2014, 16, 1-3.	2.0	2
30	Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control) Tj ETQq0 0 0 rgBTi/O verlock 110 Tf 50 2	2.0	110
31	Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet, The, 2014, 383, 1889-1898.	13.7	71
32	Analysis of Recent Papers in Hypertension. Journal of Clinical Hypertension, 2013, 15, 2-4.	2.0	7
33	The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). Journal of Diabetes and Its Complications, 2013, 27, 280-286.	2.3	41
34	Determining the Relative Antihypertensive Potency and Relative Cardiovascular Risk Reduction Associated With Different Thiazide and Thiazideâ€”Type Diuretics. Journal of Clinical Hypertension, 2013, 15, 359-361.	2.0	3
35	Analysis of Recent Papers in Hypertension Initial Combination Therapy Provides More Prompt Blood Pressure Control and Reduces Cardiovascular Events But Remains Underutilized. Journal of Clinical Hypertension, 2013, 15, 523-525.	2.0	1
36	Exposure to Air Pollution Increases the Incidence of Hypertension and Diabetes in Black Women Living in Los Angeles. Journal of Clinical Hypertension, 2012, 14, 819-820.	2.0	11

#	ARTICLE	IF	CITATIONS
37	NHANES Data Highlight the Clinical Characteristics of Those With Poorly Controlled Hypertension. Journal of Clinical Hypertension, 2012, 14, 267-268.	2.0	3
38	New British Guidelines Mandate Ambulatory Blood Pressure Monitoring to Diagnose Hypertension in All Patients: Not Ready for Prime Time in the United States. Journal of Clinical Hypertension, 2011, 13, 785-786.	2.0	15
39	A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition. Postgraduate Medicine, 2011, 123, 38-45.	2.0	12
40	Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integrated Blood Pressure Control, 2010, 3, 91.	1.2	5
41	Lessons learned from the ONTARGET and TRANSCEND trials. Current Atherosclerosis Reports, 2009, 11, 371-376.	4.8	6
42	Angiotensin Receptor Blockers: Role in Hypertension Management, Cardiovascular Risk Reduction, and Nephropathy. Southern Medical Journal, 2009, 102, S1-S12.	0.7	14
43	Shifting Paradigms in Defining and Treating Hypertension: Addressing Global Risk With Combination Therapy. Journal of Clinical Hypertension, 2008, 10, 2-3.	2.0	7
44	Recognizing the Link Between CKD and CVD in the Primary Care Setting: Accurate and Early Diagnosis for Timely and Appropriate Intervention. Southern Medical Journal, 2007, 100, 499-505.	0.7	12
45	Management of Global Risk Across the Continuum of Hypertensive Heart Disease. Journal of Clinical Hypertension, 2006, 8, 21-30.	2.0	2
46	Analysis of Recent Papers in Hypertension—Jan Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2006, 8, 823-825.	2.0	1
47	Treating the Cardiometabolic Syndrome: An Opportunity to Provide Comprehensive Cardiovascular Risk Reduction. Journal of the Cardiometabolic Syndrome, 2006, 1, 358-361.	1.7	7
48	Analysis of Recent Papers in Hypertension —Jan Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2005, 7, 183-187.	2.0	0
49	Analysis of Recent Papers in Hypertension —Jan Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2005, 7, 252-253.	2.0	1
50	Analysis of Recent Papers in Hypertension—Jan Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2005, 7, 313-316.	2.0	0
51	Analysis of Recent Papers in Hypertension—Jan Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2005, 7, 430-432.	2.0	0
52	Analysis of Recent Papers in Hypertension—Jan Basile, MD Senior Editor. Journal of Clinical Hypertension, 2004, 6, 722-724.	2.0	0
53	A Statewide Primary Care Approach to Cardiovascular Risk Factor Control in High-Risk Diabetic and Nondiabetic Patients With Hypertension. Journal of Clinical Hypertension, 2004, 6, 18-25.	2.0	21
54	Analysis of Recent Papers in Hypertension. Journal of Clinical Hypertension, 2004, 6, 96-101.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Analysis of Recent Papers in Hypertension—Jan N. Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2004, 6, 342-346.	2.0	0
56	The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension. Journal of Clinical Hypertension, 2004, 6, 621-629.	2.0	62
57	Analysis of Recent Papers in Hypertension—Jan Basile, MD, Senior Editor. Journal of Clinical Hypertension, 2004, 6, 530-531.	2.0	1
58	Analysis of Recent Papers in Hypertension. Journal of Clinical Hypertension, 2003, 5, 78-80.	2.0	0
59	Risk factor treatment and control in the stroke belt. American Journal of Hypertension, 2003, 16, A8.	2.0	0
60	Optimizing antihypertensivetreatment in clinical practice. American Journal of Hypertension, 2003, 16, 13-17.	2.0	16
61	Systolic Blood Pressure Elevation. Drugs and Aging, 2003, 20, 287-288.	2.7	0
62	Titration of β -blockers in heart failure. Postgraduate Medicine, 2003, 113, 63-70.	2.0	9
63	Analysis of recent papers in hypertension. Need for more aggressive blood pressure control in diabetes. Journal of Clinical Hypertension, 2003, 5, 352-3.	2.0	0
64	Hypertension in the Elderly: A Review of the Importance of Systolic Blood Pressure Elevation. Journal of Clinical Hypertension, 2002, 4, 108-119.	2.0	25
65	Halting the progression of heart failure: finding the optimal combination therapy.. Cleveland Clinic Journal of Medicine, 2002, 69, 104-105.	1.3	0
66	Gaining weight increases the risk for the development of heart failure. Journal of Clinical Hypertension, 2002, 4, 433.	2.0	0
67	Coffee intake over 33 years is not associated with developing hypertension. Journal of Clinical Hypertension, 2002, 4, 434.	2.0	0
68	Serial hemodynamic measurements allow better blood pressure control than clinical judgment in those with refractory hypertension. Journal of Clinical Hypertension, 2002, 4, 434-5.	2.0	1